how to make cryptocurrency People also ask

Borui Medicine: Carboprost injection is planned to win the bid for the national centralized drug procurement. Borui Medicine announced that in the tenth batch of national centralized drug procurement in which Borui Pharmaceutical, a wholly-owned subsidiary, participated, carboprost tromethamine injection is planned to win the bid. This product is mainly used for 13-20 weeks pregnant abortion and postpartum hemorrhage. The specification is 1 ml: 250μ g, and the proposed bid price is 16.96 yuan/piece. In the first year, the agreed purchase base is 220,400 pieces, which are mainly supplied to Henan, Hubei, Guangxi, Shaanxi, Gansu, Ningxia and other provinces. If the contract is finally selected and signed, it will help the product to quickly open the domestic market and enhance the market share and brand influence of the company. The product obtained the drug registration certificate in March 2024, and has not yet generated sales revenue.The International (Xiong 'an) Robot Industry Alliance was formally established. On December 12th, it was learned from the 2024 xiong'an new area Intelligent Robot Industry Development Conference held in xiong'an new area, Hebei Province that the International (Xiong 'an) Robot Industry Alliance and Xiong 'an Robot Innovation and Technology Research Institute were formally established. "As an important representative of the future industry, the intelligent robot industry is in a critical period of rapid development. The establishment of the International (Xiong 'an) Robot Industry Alliance will strongly promote the development of Xiong 'an robot industry, and the establishment of Xiong 'an Robot Innovation Technology Research Institute will provide strong technical support for the sustainable development of intelligent robot industry, marking a solid step in technology research and development and innovation of xiong'an new area robot industry. " Zhang Qin, former vice chairman of China Association for Science and Technology, said. (xinhuanet)Yiling Pharmaceutical Co., Ltd.: The application for clinical trial of Lianhua Yuping Granule was approved, and Yiling Pharmaceutical announced that Beijing Yiling, a wholly-owned subsidiary, received the Notice of Approval for Clinical Trial of Drugs approved and issued by National Medical Products Administration on December 12, 2024, and agreed to carry out clinical trial of Lianhua Yuping Granule for qi deficiency syndrome of common cold.

Pimco and Fidelity believe that the economic outlook in the euro zone is weak, and the European Central Bank has cut interest rates by more than market expectations. Investors such as Pimco and Fidelity International believe that the economic outlook in Europe is bleak, which may force policymakers to cut interest rates by more than market expectations. The latest market pricing shows that the European Central Bank is expected to cut its key interest rate to 1.75% next year. The bank cut interest rates for the third time in a row on Thursday, to 3%. However, Fidelity said that the borrowing cost may be further reduced to 1.5%, and Pimco also believed that there was a risk of a larger interest rate cut. Further repricing may aggravate the rise of European bonds, which have outperformed the US and UK bond markets in 2024. A Bloomberg index, which tracks the return of euro bonds, has risen by more than 3% this year, while the corresponding indexes of US bonds and British bonds have risen by 2% and fallen by 2% respectively. "Market expectations are still more hawkish than we expected," said Salman Ahmed, global head of macro and strategic asset allocation at Fidelity. "If downside risks become a reality, then the European Central Bank may cut interest rates further."Borui Medicine: Carboprost injection is planned to win the bid for the national centralized drug procurement. Borui Medicine announced that in the tenth batch of national centralized drug procurement in which Borui Pharmaceutical, a wholly-owned subsidiary, participated, carboprost tromethamine injection is planned to win the bid. This product is mainly used for 13-20 weeks pregnant abortion and postpartum hemorrhage. The specification is 1 ml: 250μ g, and the proposed bid price is 16.96 yuan/piece. In the first year, the agreed purchase base is 220,400 pieces, which are mainly supplied to Henan, Hubei, Guangxi, Shaanxi, Gansu, Ningxia and other provinces. If the contract is finally selected and signed, it will help the product to quickly open the domestic market and enhance the market share and brand influence of the company. The product obtained the drug registration certificate in March 2024, and has not yet generated sales revenue.Alipay launched the commercial insurance code, and the first batch has been connected to Taikang and Zhongan medical insurance. On December 13th, Alipay launched the commercial insurance code. This means that after the patient has paid the medical insurance for hospitalization, if it needs to be supplemented, he can directly use the business insurance code to apply for prepayment of hospitalization expenses, and then initiate reimbursement claims to the insurance company. At present, users can open this service by searching for "business insurance code" on Alipay, and can apply for medical treatment quota according to the prompts. The first phase of the commercial insurance code has covered the mainstream millions of medical insurance under Taikang Online and Zhongan Online, and will cover more insurance institutions and insurance types in the future.

Barclays: Raise the target price of Standard Chartered from 940p to 970p.European Central Bank Management Committee Muller: It is expected that Europe will recover slowly.The CSRC approved the registration application of Jiangnan New Materials Technology Co., Ltd. for initial public offering of shares.